Loading...

The global impact of Precision Medicine Group.
As it happens.

Impact, observations, and insights on the evolving healthcare landscape.

Webinar: The Hitchhiker’s Guide to CGTx in 2023

2023-01-25T12:33:53-05:00Cell & Gene Therapy, Events|

Cell & gene therapy advancement has increased at an immense rate over the past decade. With the right tools and guidance, patients can receive new forms of treatments. Staying up to date with progress in the field is as important as ever with the constant strive to improve technology, especially in areas like regulatory pathways, novel technologies, and CMC and manufacturing trends.

Sponsored by Precision ADVANCE, this Life Science Connect webinar will convene leading advanced therapy experts to discuss innovation and expectations for advanced therapies in 2023. This discussion will be moderated by Andy Kinley (VP of Innovation & Clinical Science, Precision for Medicine), and include insights from Peter Andersen (CSO, Vita Therapeutics), Deb Phippard (CSO, Precision for Medicine), Palani Palaniappan (CTO, Flagship Pioneering), Phil Cyr (SVP, Precision Value & Health), and Charlie Harper (VP, Project Farma).

(more…)

On-Demand: Overcoming Manufacturing Challenges for Advanced Medicines

2022-11-03T10:27:15-04:00Cell & Gene Therapy, Events|

Sponsored by Precision ADVANCE, this Endpoints webinar with convene leading advanced therapy experts to discuss manufacturing strategies for next-generation medicines. This discussion will be moderated by Adam Pfeiffer (VP of Strategy, Project Farma), and include insights from Charlie Harper (VP, Project Farma), Brian Stamper (VP of Cell Therapy Operations, Immunomic Therapeutics Inc.), Jim Watson (VP, Project Farma), Brian Riley (Chief Manufacturing Officer, Beam Therapeutics), and Chad Salisbury (SVP, Project Farma).

(more…)

On-Demand: Gene Therapy Roundup—What to know now from the lab to the FDA

2022-11-02T15:59:47-04:00Cell & Gene Therapy, Events|

Gene therapy continues to evolve rapidly – from the science to the regulatory requirements. To give you a greater perspective on recent developments, this panel discussion brings together gene therapy experts across assay development, regulatory submissions, and clinical trial strategy who will share observations from the front lines on a multitude of gene therapy and rare disease projects.

(more…)

On Demand: Cell & Gene Day

2022-12-19T13:48:20-05:00Cell & Gene Therapy, Events, Thought Leadership|

As a wave of up-and-coming cell and gene therapies eye the path to approval soon, a combination of uncertainties threatens the waters ahead. A lack of talent, shortage of manufacturing, standardization, and shifting infrastructure are just the beginning of a range of potential issues.

Join Endpoints News and Precision ADVANCE for Cell & Gene Day, a free virtual event on August 24, from 12:00-4:00 PM ET where we convene three distinguished panels of experts to find out where the field stands today and explore funding, development and launch strategies to smooth out the ride to commercialization. You will hear from successful innovators from each facet of the CGTx landscape, including executives from Blackstone, Flagship Pioneering, Monograph Capital, Alliance for Regenerative Medicine, Satellite Bio, Cellevolve Bio, and more.

On Demand Panel: Meeting on the Med, 2022

2022-06-29T14:52:49-04:00Cell & Gene Therapy, Events|

This panel discussion, at ARM’s 2022 Meeting on the Med conference, focused on the sector’s continued success and challenges that lie ahead in research and development, manufacturing, regulatory, pricing, and reimbursement. Watch our panel of industry experts discuss the future of advanced medicines with emerging technologies like gene editing, non-viral delivery methods, and allogeneic cell therapies.

(more…)

On-Demand: Public Markets’ Impact on Manufacturing Advanced Therapies

2022-07-26T10:33:56-04:00Events|

Commercial viability for cell and gene therapy requires the right approach to manufacturing. This webinar, sponsored by Project Farma and Precision ADVANCE addressed public market trends and their impact on the decision to manufacture cell and gene therapies internally or with an external supplier such as a CDMO. Our panel of experts discussed their organizations’ pipeline, the advanced therapy investment landscape, and the regulatory, manufacturing, and commercial requirements for successfully bringing an advanced therapy to market.

(more…)

Load More Posts